A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Respiratory Syncytial Virus (RSV) Prefusion F Subunit Vaccine in Older Adults in Koreasoansm01Wed, 01/28/2026 - 01:35 Abrysvo® PF-06928316 (RSVpreF) PHASE III Mon, 10/07/2024 - 12:00 Mon, 02/03/2025 - 12:00 NCT06593587 C3671053 Public Disclosure Synopsis .pdf (92.03 KB) N https://clinicaltrials.gov/study/NCT06593587?term=C3671053&rank=1 C3671053
